Comparative Pharmacology
Head-to-head clinical analysis: EXELDERM versus LOTRIMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXELDERM versus LOTRIMIN.
EXELDERM vs LOTRIMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply a thin layer to affected skin twice daily (morning and evening).
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
None Documented
None Documented
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
Category C
Category C
Topical Antifungal
Topical Antifungal